E.W. Scripps Seeks Shareholder Ratification for Poison Pill Amidst CEO's $10M Performance Award
SSP has more than doubled off its 52-week low of $1.36.
Summary
E.W. Scripps is seeking shareholder ratification for a defensive Shareholder Rights Plan and detailing its CEO's new $10 million performance-based compensation package, alongside proposals for director elections at its upcoming annual meeting.
Key Events · Corporate Governance and Compliance · SSP
-
Shareholder Rights Plan Ratification
The company is seeking shareholder ratification for a Shareholder Rights Plan (poison pill) adopted on November 25, 2025, following an unsolicited acquisition proposal. The plan's exercise price is $2.19, and it includes a 'flip-in' trigger allowing non-acquiring shareholders to purchase shares at a discount if a person or group acquires 10% or more of outstanding Class A Common Shares. The plan will expire if not ratified at the 2026 annual meeting.
-
CEO Employment Agreement and Performance Award
Details of the CEO's extended employment agreement through December 31, 2029, are provided, including an annual base salary of at least $1.4 million and a target long-term incentive of at least $4.7 million for 2026. A one-time $10 million performance-based cash award is included, vesting based on EBITDA growth targets and a $10.00 stock price hurdle by December 31, 2029. This follows the 8-K filing on 2026-02-26.
-
Board Expansion and Director Nominee
The Board voted in February 2026 to increase its size from 11 to 12 directors, effective at the annual meeting. A new nominee, Tracy Ward, is proposed, whose qualifications and connection to the Scripps family's institutional knowledge are cited as reasons for the expansion.
-
Executive Compensation Details
The filing outlines the 2025 compensation for named executive officers, including base salaries, short-term incentives (STI), and long-term incentives (LTI). The CEO's total compensation for 2025 was $7.24 million, and average for other NEOs was $2.68 million. STI payouts for 2025 were 88-90% of target based on operating cash flow and revenue goals.
Analysis · SSP · Technology
This preliminary proxy statement details key proposals for the upcoming annual meeting, including the ratification of a Shareholder Rights Plan (poison pill) adopted in November 2025 following an unsolicited acquisition proposal. This defensive measure, with an exercise price of $2.19 (below current market price), aims to protect shareholders from coercive tactics and provide the board leverage in potential M&A. The filing also provides full details on the CEO's recently extended employment agreement, which includes a $10 million performance-based cash award tied to a $10 stock price target and EBITDA growth, a significant compensation package given the company's recent net losses. The board is also proposing to increase its size from 11 to 12 directors, adding a nominee with ties to the Scripps family's institutional knowledge. Investors should monitor the outcome of the rights plan ratification and its implications for potential M&A activity, as well as the company's ability to meet the ambitious performance targets set for executive compensation.
How filings like this one have moved
In the 30 days to Sep 16, 2026, 34.9% of the 1159 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SSP was trading at $4.63 on NASDAQ in the Technology sector, with a market capitalization of approximately $409.5M. The 52-week trading range was $1.36 to $4.98. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.